DEMAPHARMA
ActiveSummary
DEMAPHARMA has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €385,336 and a net result of €17,290. Equity is growing by about 11% per year across the filed financial years. Its solvency ranks better than 72% of 12,519 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Group and network
Holdings and subsidiaries
1 holdingHoldings 1
-
99%
According to the 2025 annual accounts of DEMAPHARMA and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
No directors read yet: 0 of 2 Gazette acts processed.